Latest news

Filters
October 19, 2021

CARB-X FUNDS THE 3RD ROUND OF DEBIOPHARM’S TARGETED ANTIBIOTIC PROGRAM TO COMBAT RESISTANT N. GONORRHOEAE INFECTIONS

Read more
October 7, 2021

Debiopharm & Dexa Medica Launch Triptorelin Collaboration to Bring New Hope To Women With Endometriosis

Read more
October 4, 2021

Debiopharm Encourages Breakthough Cancer Research In Japan Through its Competitive JCA Mauvernay Award

Read more
July 1, 2021

6e Challenge Qualité de vie du patient : cinq finalistes reçoivent 5000 francs chacun et avancent en finale

Read more
June 16, 2021

Debiopharm and Ubix Therapeutics launch research to develop a new anti-cancer modality – antibody degraducer® conjugates

Read more
June 14, 2021

Debiopharm’s CD37 antibody drug conjugate shows promising phase II results for the treatment of B-cell malignancies

Read more
April 20, 2021

Debiopharm Collaborates With Innocentive For The Launch of A Global Challenge To Develop A Single-Dose mRNA Covid-19 Vaccine

Read more
March 31, 2021

Debiopharm Launches the “IDEAL” Initiative to Strengthen the Lemanic Region as a Hub for Life Science Innvovation

Read more
March 1, 2021

Debiopharm Grants a Worldwide Exclusive License to Merck for the Development and Commercialization of Xevinapant

Read more